Philippe Calais
Equibles does not estimate personal net worth.
Get an email with a short summary when Transcode Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get RNAZ alertsAbout Philippe Calais
Philippe Calais is recorded as CEO at Transcode Therapeutics, Inc. (RNAZ) since October 6, 2025. Transcode Therapeutics, Inc. reported in an 8-K filed October 8, 2025 that Philippe Calais was appointed Chief Executive Officer, effective October 8, 2025. Transcode Therapeutics, Inc. reported in an 8-K filed October 8, 2025 that Philippe Calais was appointed Chief Executive Officer. Transcode Therapeutics, Inc. reported in an 8-K filed October 8, 2025 that Philippe Calais was appointed Chief Executive Officer, effective October 6, 2025. Equibles holds 4 filed executive changes naming Philippe Calais; each is listed under recent activity with its source filing. Transcode Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Transcode Therapeutics, Inc. includes Philippe P. Calais (CEO and Board Member), Thomas A. Fitzgerald (CEO and CFO), John Tattory (CFO) and 6 others.
“Philippe Calais, PharmD, PhD, has been appointed as TransCode's Chief Executive Officer and remains Chairman of the Board of Directors, but has stepped down from his positions on the Board's Audit Committee and Compensation Committee.”
“Philippe Calais, PharmD, PhD, has been appointed as TransCode's Chief Executive Officer and remains Chairman of the Board of Directors, but has stepped down from his positions on the Board's Audit Committee and Compensation Committee.”
Affiliation history
-
Current
2025-10-06–present
Company network
Leadership on record at Transcode Therapeutics, Inc.
- Philippe P. Calais CEO, Board Member
- Thomas A. Fitzgerald CEO, CFO
- John Tattory CFO
- Zdravka Medarova CTO
- Elizabeth Czerepak Board Member
- Erik Manting Board Member
- Jack E. Stover Board Member
- Jack Stover Board Member
- Magda Marquet Board Member